Rituximab for the first-line treatment of chronic lymphocytic leukaemia

Leukaemia (chronic lymphocytic, first line) - rituximab: review decision - March 2014 information

Appendix B: GE decision paper - March 2014 (PDF 110 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: Review Proposal - January 2014 information

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders (PDF 101 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 446 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012 information

Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information

NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia (PDF 37 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination information

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination (PDF 138 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 120 KB)

Consultee and commentator comments on the ACD

Chronic Lymphocytic Leukaemia Support Association (PDF 20 KB)

Department of Health (PDF 13 KB)

Leukaemia CARE (PDF 13 KB)

Roche (PDF 100 KB)

Royal College of Nursing (PDF 19 KB)

Royal College of Pathologists (PDF 8.3 KB)

Comments from website consultation (PDF 20 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation document information

Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report

Pre-meeting briefing (PDF 115 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report (PDF 3.61 MB)

Non-manufacturer submissions

Chronic Lymphocytic Leukaemia Support (PDF 49 KB)

Hampshire PCT (PDF 24 KB)

Royal College of Nursing (PDF 27 KB)

Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO) (PDF 89 KB)

UK CLL Forum (PDF 27 KB)

UK CLL Forum, Royal College of Pathologists & British Society for Haematology (PDF 40 KB)

Expert written personal statements

Barnard (PDF 97 KB)

Milligan (PDF 14 KB)

Pettitt (PDF 19 KB)

Williams Durkin (PDF 41 KB)

Manufacturer submission

Roche submission (PDF 4.22 MB)

Manufacturer response to clarification letter (PDF 309 KB)

Manufacturer response to supplementary clarification letter (PDF 18 KB)

NICE clarification letter (PDF 35 KB)

NICE supplementary clarification letter (PDF 16 KB)

Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report (PDF 165 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (PDF 27 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators (PDF 47 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope (PDF 74 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix (PDF 23 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope (PDF 31 KB)

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators (PDF 48 KB)